The North‐West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community‐based patient cohort
By C. Abbott, A. Carrington, H. Ashe, S. Bath, L. C. Every, J. Griffiths, A. W. Hann, A. Hussein, N. Jackson, K. Johnson and 7 more. Diabetic Medicine, 2002
1,039 citations recorded by the source corpus.
Subfields: Dermatology, Endocrinology, Diabetes and Metabolism, Surgery
View Paper: https://www.semanticscholar.org/paper/eb97edf7413d973175e19b7a5a04f9d7009f9ea3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Surgery
Citations in the corpus
- Diabetic somatic neuropathies. (2004, background): “The clinical relevance of an effect on motor but not sensory nerve function is questionable, especially as the latter is primarily responsible for the most common manifestations of human DN: severe pain and the insensate extremity, leading to ulceration and eventual amputation (52).”
- Comprehensive foot examination and risk assessment. A report of the Task Force of the Foot Care Interest Group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. (2008, background): “Screening for sensory loss with the 10-g monofilament is in widespread use across the world, and its efficacy in this regard has been confirmed in a number of trials, including the recent Seattle Diabetic Foot Study (4,21,23,24).”
- High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study (2006, background): “In addition, studies with long-term follow-up indicate that diabetic foot ulceration is a recurrent disease [34, 35].”
- Comprehensive Foot Examination and Risk Assessment (2008, background): “Screening for sensory loss with the 10-g monofilament is in widespread use across the world, and its efficacy in this regard has been confirmed in a number of trials, including the recent Seattle Diabetic Foot Study (4,21,23,24).”